24小时尿钠与尿钾排泄和心血管风险
该研究纳入六个前瞻性队列中一般健康成人的个体数据,每人至少用两份24小时尿样评估钠、钾排泄,主要终点为心血管事件(冠脉血运重建或致死/非致死性心肌梗死或卒中),各队列用统一方法分析后以随机效应荟萃分析合并。10,709名参与者平均年龄51.5±12.6岁、54.2%为女性,中位随访8.8年共确定571例心血管事件(发病率5.9/1000人年),中位24小时尿钠排泄为3270 mg(第10至90百分位2099至4899)。校正混杂因素后,尿钠越高、尿钾越低、钠钾比越高均与心血管风险升高相关(所有比较P≤0.005)。作者结论认为,多次24小时尿样所测的高钠、低钾摄入与更高心血管风险呈剂量-反应关系,这些发现可能支持在当前水平上减少钠摄入并增加钾摄入。
要点
- 中位随访8.8年,10,709名健康成人中确定571例心血管事件,发病率5.9/1000人年。
- 中位24小时尿钠排泄3270 mg(第10至90百分位2099至4899),以至少两份24小时尿样评估。
- 尿钠最高四分位与最低四分位相比,心血管事件风险比为1.60(95%CI 1.19至2.14)。
- 尿钾最高四分位与最低四分位相比,风险比为0.69(95%CI 0.51至0.91);钠钾比最高与最低四分位相比为1.62(95%CI 1.25至2.10)。
- 尿钠每增加1000 mg/日,风险增加18%(HR 1.18,95%CI 1.08至1.29);尿钾每增加1000 mg/日,风险降低18%(HR 0.82,95%CI 0.72至0.94)。
适用人群与场景
- 来自六个前瞻性队列的一般健康成人,每人至少有两份24小时尿样评估钠、钾排泄。
研究设计与关键结果
- 研究类型:基于六个前瞻性队列个体参与者数据的汇总分析,各队列用统一方法分析并以随机效应荟萃分析合并。
- 人群与随访:10,709名参与者,平均年龄51.5±12.6岁,54.2%为女性;中位随访8.8年,确定571例心血管事件,发病率5.9/1000人年。
- 主要终点:心血管事件(冠脉血运重建或致死或非致死性心肌梗死或卒中)。
- 暴露:中位24小时尿钠排泄3270 mg(第10至90百分位2099至4899)。
- 校正混杂因素后,尿钠越高、尿钾越低、钠钾比越高均与心血管风险升高相关(所有比较P≤0.005)。
- 最高与最低四分位比较:尿钠HR 1.60(95%CI 1.19至2.14),尿钾HR 0.69(95%CI 0.51至0.91),钠钾比HR 1.62(95%CI 1.25至2.10)。
- 每1000 mg/日增量:尿钠HR 1.18(95%CI 1.08至1.29),风险增加18%;尿钾HR 0.82(95%CI 0.72至0.94),风险降低18%。
证据类型、等级与局限
- 证据类型:六个前瞻性队列个体参与者数据的汇总分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,这些发现可能支持在当前水平上减少钠摄入并增加钾摄入。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The relation between sodium intake and cardiovascular disease remains controversial, owing in part to inaccurate assessment of sodium intake. Assessing 24-hour urinary excretion over a period of multiple days is considered to be an accurate method.
METHODS: We included individual-participant data from six prospective cohorts of generally healthy adults; sodium and potassium excretion was assessed with the use of at least two 24-hour urine samples per participant. The primary outcome was a cardiovascular event (coronary revascularization or fatal or nonfatal myocardial infarction or stroke). We analyzed each cohort using consistent methods and combined the results using a random-effects meta-analysis.
RESULTS: Among 10,709 participants, who had a mean (±SD) age of 51.5±12.6 years and of whom 54.2% were women, 571 cardiovascular events were ascertained during a median study follow-up of 8.8 years (incidence rate, 5.9 per 1000 person-years). The median 24-hour urinary sodium excretion was 3270 mg (10th to 90th percentile, 2099 to 4899). Higher sodium excretion, lower potassium excretion, and a higher sodium-to-potassium ratio were all associated with a higher cardiovascular risk in analyses that were controlled for confounding factors (P≤0.005 for all comparisons). In analyses that compared quartile 4 of the urinary biomarker (highest) with quartile 1 (lowest), the hazard ratios were 1.60 (95% confidence interval [CI], 1.19 to 2.14) for sodium excretion, 0.69 (95% CI, 0.51 to 0.91) for potassium excretion, and 1.62 (95% CI, 1.25 to 2.10) for the sodium-to-potassium ratio. Each daily increment of 1000 mg in sodium excretion was associated with an 18% increase in cardiovascular risk (hazard ratio, 1.18; 95% CI, 1.08 to 1.29), and each daily increment of 1000 mg in potassium excretion was associated with an 18% decrease in risk (hazard ratio, 0.82; 95% CI, 0.72 to 0.94).
CONCLUSIONS: Higher sodium and lower potassium intakes, as measured in multiple 24-hour urine samples, were associated in a dose-response manner with a higher cardiovascular risk. These findings may support reducing sodium intake and increasing potassium intake from current levels. (Funded by the American Heart Association and the National Institutes of Health.).
参考来源
- Ma Y, He FJ, Sun Q, et al. 24-Hour Urinary Sodium and Potassium Excretion and Cardiovascular Risk. N Engl J Med. 2021. PMID: 34767706. doi:10.1056/NEJMoa2109794
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。